171 related articles for article (PubMed ID: 22134350)
1. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
Pharmacogenet Genomics; 2012 Jan; 22(1):58-68. PubMed ID: 22134350
[TBL] [Abstract][Full Text] [Related]
2. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
[TBL] [Abstract][Full Text] [Related]
3. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Rha SY; Jeung HC; Choi YH; Yang WI; Yoo JH; Kim BS; Roh JK; Chung HC
Oncologist; 2007 Jun; 12(6):622-30. PubMed ID: 17602053
[TBL] [Abstract][Full Text] [Related]
4. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
[TBL] [Abstract][Full Text] [Related]
5. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
6. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
8. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
11. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Lee SY; Im SA; Park YH; Woo SY; Kim S; Choi MK; Chang W; Ahn JS; Im YH
Eur J Cancer; 2014 Mar; 50(4):698-705. PubMed ID: 24361227
[TBL] [Abstract][Full Text] [Related]
14. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
[TBL] [Abstract][Full Text] [Related]
15. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
16. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
17. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
J Thorac Oncol; 2012 Oct; 7(10):1609-17. PubMed ID: 22982660
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
[TBL] [Abstract][Full Text] [Related]
19. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
20. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Jørgensen CL; Ejlertsen B; Bjerre KD; Balslev E; Nielsen DL; Nielsen KV
BMC Cancer; 2013 Nov; 13():541. PubMed ID: 24215511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]